Humana Inc. (NYSE:HUM) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP reduced its position in Humana Inc. (NYSE:HUM - Free Report) by 21.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 587,053 shares of the insurance provider's stock after selling 163,854 shares during the quarter. Two Sigma Investments LP owned about 0.49% of Humana worth $148,941,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FPC Investment Advisory Inc. acquired a new stake in shares of Humana in the fourth quarter valued at about $27,000. Centricity Wealth Management LLC purchased a new stake in Humana during the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA raised its holdings in Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after acquiring an additional 45 shares during the last quarter. OFI Invest Asset Management purchased a new position in Humana in the 4th quarter worth approximately $33,000. Finally, Transce3nd LLC acquired a new position in shares of Humana during the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Price Performance

HUM stock opened at $237.42 on Monday. The business's fifty day moving average price is $262.94 and its 200 day moving average price is $269.57. Humana Inc. has a 12-month low of $212.45 and a 12-month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $28.65 billion, a PE ratio of 23.86, a P/E/G ratio of 2.05 and a beta of 0.49.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. Humana's revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the company posted $7.23 EPS. On average, sell-side analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.49%. The ex-dividend date is Friday, June 27th. Humana's payout ratio is currently 25.04%.

Analysts Set New Price Targets

Several research firms recently commented on HUM. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. Barclays lifted their price target on Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a report on Friday, April 11th. Guggenheim started coverage on shares of Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price objective for the company. Truist Financial cut their price objective on shares of Humana from $325.00 to $305.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Finally, Mizuho boosted their target price on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Seventeen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Humana currently has a consensus rating of "Hold" and a consensus price target of $286.81.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.